Loading organizations...
Biopharmaceutical company developing small molecule therapeutics for advanced-stage cancers and cardiometabolic diseases.
KayoThera is a Princeton, New Jersey-based biotechnology company developing novel small molecule therapeutics that target retinoid nuclear receptor pathways to treat advanced-stage cancers and cardiometabolic diseases. The preclinical-stage firm focuses on pioneering first-in-class retinoid nuclear receptor antagonists for various cancers, including breast, lung, and pancreatic, as well as obesity and diabetes. KayoThera has raised $8 million in Series A financing, led by Accelerator Life Science Partners, to advance its development programs toward the clinical stage. The company has developed three pipeline candidates through investigational new drug application-enabling work. Initial funding was provided by Foundation Venture Capital Group, and its scientific leadership includes co-founder Yibin Kang, a Princeton professor, and Scientific Strategy Board Member Kenric Hoegler. KayoThera was founded in 2019 by Mark Esposito and Yibin Kang.
KayoThera has raised $13.2M across 2 funding rounds.
KayoThera has raised $13.2M in total across 2 funding rounds.
KayoThera has raised $13.2M in total across 2 funding rounds.
KayoThera's investors include Thong Le, Andy Hill Cancer Research Endowment Fund, BioAdvance, National Institutes of Health, New Jersey Health Foundation, Pier 70 Ventures, WRF Capital, Ken Mohler, 7G Bioventures.
KayoThera has raised $13.2M across 2 funding rounds. Most recently, it raised $5.2M Series A Extension in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 19, 2023 | $5.2M Series A Extension | Thong Le | Andy Hill Cancer Research Endowment Fund, BioAdvance, National Institutes of Health, New Jersey Health Foundation, Pier 70 Ventures, WRF Capital |
| Mar 16, 2022 | $8.0M Series A | Ken Mohler | 7G Bioventures, BioAdvance |